Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment
Article Swipe
Norimitsu Kasahara
,
Hisao Imai
,
Ichiro Naruse
,
Yusuke Tsukagoshi
,
Mie Kotake
,
Noriaki Sunaga
,
Kyoichi Kaira
,
Toshitaka Maeno
,
Takayuki Asao
,
Takeshi Hisada
·
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1111/1759-7714.13526
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1111/1759-7714.13526
Background Lung cancer is the leading cause of cancer‐related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are effective for advanced non‐small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS) is an inflammation‐related score based on C‐reactive protein (CRP) and albumin concentrations, and has prognostic value in various cancer settings. This study aimed to evaluate whether GPS could predict response of NSCLC to EGFR‐TKIs. Methods This retrospective multicenter study evaluated patients with NSCLC harboring EGFR mutations who received EGFR‐TKI monotherapy from October 2006 to December 2016. GPS values were determined using CRP and albumin concentrations from before initiation of EGFR‐TKIs. The Kaplan‐Meier method and Cox proportional hazard models were used to evaluate progression‐free survival (PFS) and overall survival (OS). Results In 214 patients, 141, 43, and two patients had GPS values of 0, 1, and 2, respectively. The GPS independently predicted the efficacy of EGFR‐TKIs; good GPS (0–1) conferred significantly better PFS (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.38–0.96, P = 0.03) and OS (HR: 0.56, 95% CI: 0.33–0.96, P = 0.03). Multivariate analysis confirmed that a good GPS (0–1) independently predicted good PFS and OS among patients who had PS of 0–1. Good GPS (0–1) independently predicted good OS among patients receiving treatment in first‐line settings. Conclusions The GPS independently predicted the efficacy of EGFR‐TKIs for EGFR ‐mutated NSCLC; however, further studies are needed to validate our findings. Key points Significant findings of the study Glasgow prognostic score (GPS) independently predicted the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) treatment for EGFR ‐mutated NSCLC. What this study adds The findings presented in this paper will help to identify patients who will be expected to experience limited or no response to EGFR‐TKI treatment by using GPS.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1111/1759-7714.13526
- OA Status
- gold
- Cited By
- 12
- References
- 36
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3029628102
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3029628102Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1111/1759-7714.13526Digital Object Identifier
- Title
-
Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving
EGFR‐TKI treatmentWork title - Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2020Year of publication
- Publication date
-
2020-06-03Full publication date if available
- Authors
-
Norimitsu Kasahara, Hisao Imai, Ichiro Naruse, Yusuke Tsukagoshi, Mie Kotake, Noriaki Sunaga, Kyoichi Kaira, Toshitaka Maeno, Takayuki Asao, Takeshi HisadaList of authors in order
- Landing page
-
https://doi.org/10.1111/1759-7714.13526Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1111/1759-7714.13526Direct OA link when available
- Concepts
-
Medicine, Internal medicine, Hazard ratio, Oncology, Lung cancer, Proportional hazards model, Erlotinib, Cancer, Confidence interval, Epidermal growth factor receptorTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
12Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1, 2024: 1, 2023: 1, 2022: 4, 2021: 5Per-year citation counts (last 5 years)
- References (count)
-
36Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3029628102 |
|---|---|
| doi | https://doi.org/10.1111/1759-7714.13526 |
| ids.doi | https://doi.org/10.1111/1759-7714.13526 |
| ids.mag | 3029628102 |
| ids.openalex | https://openalex.org/W3029628102 |
| fwci | 1.54590966 |
| type | article |
| title | Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving |
| biblio.issue | 8 |
| biblio.volume | 11 |
| biblio.last_page | 2195 |
| biblio.first_page | 2188 |
| grants[0].funder | https://openalex.org/F4320334764 |
| grants[0].award_id | |
| grants[0].funder_display_name | Japan Society for the Promotion of Science |
| topics[0].id | https://openalex.org/T10417 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Lung Cancer Treatments and Mutations |
| topics[1].id | https://openalex.org/T12334 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9994000196456909 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Lung Cancer Research Studies |
| topics[2].id | https://openalex.org/T10185 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9983999729156494 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2734 |
| topics[2].subfield.display_name | Pathology and Forensic Medicine |
| topics[2].display_name | Lymphoma Diagnosis and Treatment |
| funders[0].id | https://openalex.org/F4320334764 |
| funders[0].ror | https://ror.org/00hhkn466 |
| funders[0].display_name | Japan Society for the Promotion of Science |
| is_xpac | False |
| apc_list.value | 2000 |
| apc_list.currency | USD |
| apc_list.value_usd | 2000 |
| apc_paid.value | 2000 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2000 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8454552292823792 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C126322002 |
| concepts[1].level | 1 |
| concepts[1].score | 0.7373733520507812 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[1].display_name | Internal medicine |
| concepts[2].id | https://openalex.org/C207103383 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7078622579574585 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[2].display_name | Hazard ratio |
| concepts[3].id | https://openalex.org/C143998085 |
| concepts[3].level | 1 |
| concepts[3].score | 0.6953287720680237 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[3].display_name | Oncology |
| concepts[4].id | https://openalex.org/C2776256026 |
| concepts[4].level | 2 |
| concepts[4].score | 0.6898398399353027 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q47912 |
| concepts[4].display_name | Lung cancer |
| concepts[5].id | https://openalex.org/C50382708 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5858392715454102 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q223218 |
| concepts[5].display_name | Proportional hazards model |
| concepts[6].id | https://openalex.org/C2778087573 |
| concepts[6].level | 4 |
| concepts[6].score | 0.5210096836090088 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q418369 |
| concepts[6].display_name | Erlotinib |
| concepts[7].id | https://openalex.org/C121608353 |
| concepts[7].level | 2 |
| concepts[7].score | 0.48899710178375244 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[7].display_name | Cancer |
| concepts[8].id | https://openalex.org/C44249647 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4713399112224579 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[8].display_name | Confidence interval |
| concepts[9].id | https://openalex.org/C2779438470 |
| concepts[9].level | 3 |
| concepts[9].score | 0.44548359513282776 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q424401 |
| concepts[9].display_name | Epidermal growth factor receptor |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8454552292823792 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/internal-medicine |
| keywords[1].score | 0.7373733520507812 |
| keywords[1].display_name | Internal medicine |
| keywords[2].id | https://openalex.org/keywords/hazard-ratio |
| keywords[2].score | 0.7078622579574585 |
| keywords[2].display_name | Hazard ratio |
| keywords[3].id | https://openalex.org/keywords/oncology |
| keywords[3].score | 0.6953287720680237 |
| keywords[3].display_name | Oncology |
| keywords[4].id | https://openalex.org/keywords/lung-cancer |
| keywords[4].score | 0.6898398399353027 |
| keywords[4].display_name | Lung cancer |
| keywords[5].id | https://openalex.org/keywords/proportional-hazards-model |
| keywords[5].score | 0.5858392715454102 |
| keywords[5].display_name | Proportional hazards model |
| keywords[6].id | https://openalex.org/keywords/erlotinib |
| keywords[6].score | 0.5210096836090088 |
| keywords[6].display_name | Erlotinib |
| keywords[7].id | https://openalex.org/keywords/cancer |
| keywords[7].score | 0.48899710178375244 |
| keywords[7].display_name | Cancer |
| keywords[8].id | https://openalex.org/keywords/confidence-interval |
| keywords[8].score | 0.4713399112224579 |
| keywords[8].display_name | Confidence interval |
| keywords[9].id | https://openalex.org/keywords/epidermal-growth-factor-receptor |
| keywords[9].score | 0.44548359513282776 |
| keywords[9].display_name | Epidermal growth factor receptor |
| language | en |
| locations[0].id | doi:10.1111/1759-7714.13526 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S37904752 |
| locations[0].source.issn | 1759-7706, 1759-7714 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1759-7706 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Thoracic Cancer |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_lineage_names | Wiley |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Thoracic Cancer |
| locations[0].landing_page_url | https://doi.org/10.1111/1759-7714.13526 |
| locations[1].id | pmh:oai:doaj.org/article:7d83077e9cd943e6b42f9d183f14d0f2 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S4306401280 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[1].source.host_organization | |
| locations[1].source.host_organization_name | |
| locations[1].license | cc-by-sa |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | article |
| locations[1].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Thoracic Cancer, Vol 11, Iss 8, Pp 2188-2195 (2020) |
| locations[1].landing_page_url | https://doaj.org/article/7d83077e9cd943e6b42f9d183f14d0f2 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:7396379 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Thorac Cancer |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7396379 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5091454845 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-6971-7411 |
| authorships[0].author.display_name | Norimitsu Kasahara |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210164827 |
| authorships[0].affiliations[0].raw_affiliation_string | Innovative Medical Research Center Gunma University Hospital Maebashi Japan |
| authorships[0].institutions[0].id | https://openalex.org/I4210164827 |
| authorships[0].institutions[0].ror | https://ror.org/05kq1z994 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210164827 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | Gunma University Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Norimitsu Kasahara |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Innovative Medical Research Center Gunma University Hospital Maebashi Japan |
| authorships[1].author.id | https://openalex.org/A5035023922 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-3097-4255 |
| authorships[1].author.display_name | Hisao Imai |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I8588240 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine Comprehensive Cancer Center, International Medical Center, Saitama Medical University Saitama Japan |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I4210164148 |
| authorships[1].affiliations[1].raw_affiliation_string | Division of Respiratory Medicine Gunma Prefectural Cancer Center Ota Japan |
| authorships[1].institutions[0].id | https://openalex.org/I4210164148 |
| authorships[1].institutions[0].ror | https://ror.org/054z08865 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210164148 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Hyogo Prefectural Cancer Center |
| authorships[1].institutions[1].id | https://openalex.org/I8588240 |
| authorships[1].institutions[1].ror | https://ror.org/04zb31v77 |
| authorships[1].institutions[1].type | education |
| authorships[1].institutions[1].lineage | https://openalex.org/I8588240 |
| authorships[1].institutions[1].country_code | JP |
| authorships[1].institutions[1].display_name | Saitama Medical University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Hisao Imai |
| authorships[1].is_corresponding | True |
| authorships[1].raw_affiliation_strings | Department of Respiratory Medicine Comprehensive Cancer Center, International Medical Center, Saitama Medical University Saitama Japan, Division of Respiratory Medicine Gunma Prefectural Cancer Center Ota Japan |
| authorships[2].author.id | https://openalex.org/A5108560188 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Ichiro Naruse |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210102403 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine Hidaka Hospital Takasaki Japan |
| authorships[2].institutions[0].id | https://openalex.org/I4210102403 |
| authorships[2].institutions[0].ror | https://ror.org/01cxg6q60 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210102403 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Hidaka Hospital |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Ichiro Naruse |
| authorships[2].is_corresponding | True |
| authorships[2].raw_affiliation_strings | Department of Respiratory Medicine Hidaka Hospital Takasaki Japan |
| authorships[3].author.id | https://openalex.org/A5034689164 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Yusuke Tsukagoshi |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I165735259 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Japan |
| authorships[3].institutions[0].id | https://openalex.org/I165735259 |
| authorships[3].institutions[0].ror | https://ror.org/046fm7598 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I165735259 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Gunma University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Yusuke Tsukagoshi |
| authorships[3].is_corresponding | True |
| authorships[3].raw_affiliation_strings | Department of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Japan |
| authorships[4].author.id | https://openalex.org/A5064369566 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-3331-3527 |
| authorships[4].author.display_name | Mie Kotake |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210164148 |
| authorships[4].affiliations[0].raw_affiliation_string | Division of Respiratory Medicine Gunma Prefectural Cancer Center Ota Japan |
| authorships[4].institutions[0].id | https://openalex.org/I4210164148 |
| authorships[4].institutions[0].ror | https://ror.org/054z08865 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210164148 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Hyogo Prefectural Cancer Center |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Mie Kotake |
| authorships[4].is_corresponding | True |
| authorships[4].raw_affiliation_strings | Division of Respiratory Medicine Gunma Prefectural Cancer Center Ota Japan |
| authorships[5].author.id | https://openalex.org/A5042736030 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-5966-4579 |
| authorships[5].author.display_name | Noriaki Sunaga |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I165735259 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Japan |
| authorships[5].institutions[0].id | https://openalex.org/I165735259 |
| authorships[5].institutions[0].ror | https://ror.org/046fm7598 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I165735259 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Gunma University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Noriaki Sunaga |
| authorships[5].is_corresponding | True |
| authorships[5].raw_affiliation_strings | Department of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Japan |
| authorships[6].author.id | https://openalex.org/A5033780369 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-5548-7686 |
| authorships[6].author.display_name | Kyoichi Kaira |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I8588240 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine Comprehensive Cancer Center, International Medical Center, Saitama Medical University Saitama Japan |
| authorships[6].institutions[0].id | https://openalex.org/I8588240 |
| authorships[6].institutions[0].ror | https://ror.org/04zb31v77 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I8588240 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Saitama Medical University |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Kyoichi Kaira |
| authorships[6].is_corresponding | True |
| authorships[6].raw_affiliation_strings | Department of Respiratory Medicine Comprehensive Cancer Center, International Medical Center, Saitama Medical University Saitama Japan |
| authorships[7].author.id | https://openalex.org/A5081624481 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-8428-1617 |
| authorships[7].author.display_name | Toshitaka Maeno |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I165735259 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Japan |
| authorships[7].institutions[0].id | https://openalex.org/I165735259 |
| authorships[7].institutions[0].ror | https://ror.org/046fm7598 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I165735259 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | Gunma University |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Toshitaka Maeno |
| authorships[7].is_corresponding | True |
| authorships[7].raw_affiliation_strings | Department of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Japan |
| authorships[8].author.id | https://openalex.org/A5080241378 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Takayuki Asao |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210164827 |
| authorships[8].affiliations[0].raw_affiliation_string | Innovative Medical Research Center Gunma University Hospital Maebashi Japan |
| authorships[8].institutions[0].id | https://openalex.org/I4210164827 |
| authorships[8].institutions[0].ror | https://ror.org/05kq1z994 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210164827 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | Gunma University Hospital |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Takayuki Asao |
| authorships[8].is_corresponding | True |
| authorships[8].raw_affiliation_strings | Innovative Medical Research Center Gunma University Hospital Maebashi Japan |
| authorships[9].author.id | https://openalex.org/A5086397728 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-3862-1887 |
| authorships[9].author.display_name | Takeshi Hisada |
| authorships[9].countries | JP |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I165735259 |
| authorships[9].affiliations[0].raw_affiliation_string | Graduate School of Health Sciences Gunma University Maebashi Japan |
| authorships[9].institutions[0].id | https://openalex.org/I165735259 |
| authorships[9].institutions[0].ror | https://ror.org/046fm7598 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I165735259 |
| authorships[9].institutions[0].country_code | JP |
| authorships[9].institutions[0].display_name | Gunma University |
| authorships[9].author_position | last |
| authorships[9].raw_author_name | Takeshi Hisada |
| authorships[9].is_corresponding | True |
| authorships[9].raw_affiliation_strings | Graduate School of Health Sciences Gunma University Maebashi Japan |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1111/1759-7714.13526 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2020-06-05T00:00:00 |
| display_name | Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10417 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Lung Cancer Treatments and Mutations |
| related_works | https://openalex.org/W1994763147, https://openalex.org/W2120992361, https://openalex.org/W2023597833, https://openalex.org/W2076668512, https://openalex.org/W2541392164, https://openalex.org/W2360123363, https://openalex.org/W2168841302, https://openalex.org/W2896649837, https://openalex.org/W2035762060, https://openalex.org/W2103997800 |
| cited_by_count | 12 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 1 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 1 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 4 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 5 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1111/1759-7714.13526 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S37904752 |
| best_oa_location.source.issn | 1759-7706, 1759-7714 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1759-7706 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Thoracic Cancer |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_lineage_names | Wiley |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Thoracic Cancer |
| best_oa_location.landing_page_url | https://doi.org/10.1111/1759-7714.13526 |
| primary_location.id | doi:10.1111/1759-7714.13526 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S37904752 |
| primary_location.source.issn | 1759-7706, 1759-7714 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1759-7706 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Thoracic Cancer |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_lineage_names | Wiley |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Thoracic Cancer |
| primary_location.landing_page_url | https://doi.org/10.1111/1759-7714.13526 |
| publication_date | 2020-06-03 |
| publication_year | 2020 |
| referenced_works | https://openalex.org/W2911188335, https://openalex.org/W2915478882, https://openalex.org/W2132157071, https://openalex.org/W2129360604, https://openalex.org/W2111662961, https://openalex.org/W2160982674, https://openalex.org/W2096198395, https://openalex.org/W2171139285, https://openalex.org/W2560717039, https://openalex.org/W2770828094, https://openalex.org/W2104347254, https://openalex.org/W2293531514, https://openalex.org/W2169372773, https://openalex.org/W2079725791, https://openalex.org/W1995287920, https://openalex.org/W2091553144, https://openalex.org/W1981187546, https://openalex.org/W1964795510, https://openalex.org/W2085186223, https://openalex.org/W1982242786, https://openalex.org/W2122377564, https://openalex.org/W1996725479, https://openalex.org/W2765522984, https://openalex.org/W2019607817, https://openalex.org/W2408455674, https://openalex.org/W2310000709, https://openalex.org/W2780332371, https://openalex.org/W2901072592, https://openalex.org/W2022463221, https://openalex.org/W2051974520, https://openalex.org/W1844382883, https://openalex.org/W1988902102, https://openalex.org/W1494972973, https://openalex.org/W2103087410, https://openalex.org/W2048991379, https://openalex.org/W1998638563 |
| referenced_works_count | 36 |
| abstract_inverted_index.= | 175, 185 |
| abstract_inverted_index.P | 174, 184 |
| abstract_inverted_index.a | 191 |
| abstract_inverted_index.0, | 145 |
| abstract_inverted_index.1, | 146 |
| abstract_inverted_index.2, | 148 |
| abstract_inverted_index.In | 133 |
| abstract_inverted_index.OS | 178, 200, 214 |
| abstract_inverted_index.PS | 205 |
| abstract_inverted_index.an | 44 |
| abstract_inverted_index.be | 290 |
| abstract_inverted_index.by | 301 |
| abstract_inverted_index.in | 59, 219, 280 |
| abstract_inverted_index.is | 3, 43 |
| abstract_inverted_index.no | 36, 296 |
| abstract_inverted_index.of | 7, 73, 111, 144, 156, 206, 229, 248, 259 |
| abstract_inverted_index.on | 48 |
| abstract_inverted_index.or | 35, 295 |
| abstract_inverted_index.to | 66, 75, 96, 123, 240, 285, 292, 298 |
| abstract_inverted_index.214 | 134 |
| abstract_inverted_index.43, | 137 |
| abstract_inverted_index.95% | 169, 181 |
| abstract_inverted_index.CI: | 182 |
| abstract_inverted_index.CRP | 104 |
| abstract_inverted_index.Cox | 117 |
| abstract_inverted_index.GPS | 69, 99, 142, 151, 159, 193, 209, 224 |
| abstract_inverted_index.Key | 244 |
| abstract_inverted_index.PFS | 164, 198 |
| abstract_inverted_index.The | 38, 113, 150, 223, 277 |
| abstract_inverted_index.and | 52, 55, 105, 116, 128, 138, 147, 177, 199 |
| abstract_inverted_index.are | 19, 238 |
| abstract_inverted_index.for | 21, 231, 269 |
| abstract_inverted_index.had | 141, 204 |
| abstract_inverted_index.has | 56 |
| abstract_inverted_index.our | 242 |
| abstract_inverted_index.the | 4, 154, 227, 249, 257 |
| abstract_inverted_index.two | 139 |
| abstract_inverted_index.who | 89, 203, 288 |
| abstract_inverted_index.(HR: | 179 |
| abstract_inverted_index.141, | 136 |
| abstract_inverted_index.2006 | 95 |
| abstract_inverted_index.EGFR | 29, 87, 232, 270 |
| abstract_inverted_index.GPS. | 303 |
| abstract_inverted_index.Good | 208 |
| abstract_inverted_index.Lung | 1 |
| abstract_inverted_index.This | 63, 78 |
| abstract_inverted_index.What | 273 |
| abstract_inverted_index.adds | 276 |
| abstract_inverted_index.cell | 24 |
| abstract_inverted_index.from | 93, 108 |
| abstract_inverted_index.good | 158, 192, 197, 213 |
| abstract_inverted_index.help | 284 |
| abstract_inverted_index.lung | 25 |
| abstract_inverted_index.some | 31 |
| abstract_inverted_index.that | 190 |
| abstract_inverted_index.this | 274, 281 |
| abstract_inverted_index.used | 122 |
| abstract_inverted_index.were | 101, 121 |
| abstract_inverted_index.will | 283, 289 |
| abstract_inverted_index.with | 84 |
| abstract_inverted_index.(CRP) | 51 |
| abstract_inverted_index.(GPS) | 42, 254 |
| abstract_inverted_index.(OS). | 131 |
| abstract_inverted_index.(PFS) | 127 |
| abstract_inverted_index.0.03) | 176 |
| abstract_inverted_index.0.56, | 180 |
| abstract_inverted_index.0.59, | 168 |
| abstract_inverted_index.2016. | 98 |
| abstract_inverted_index.NSCLC | 74, 85 |
| abstract_inverted_index.[CI]: | 172 |
| abstract_inverted_index.[HR]: | 167 |
| abstract_inverted_index.aimed | 65 |
| abstract_inverted_index.among | 201, 215 |
| abstract_inverted_index.based | 47 |
| abstract_inverted_index.cause | 6 |
| abstract_inverted_index.could | 70 |
| abstract_inverted_index.paper | 282 |
| abstract_inverted_index.ratio | 166 |
| abstract_inverted_index.score | 41, 46, 253 |
| abstract_inverted_index.study | 64, 81, 250, 275 |
| abstract_inverted_index.using | 103, 302 |
| abstract_inverted_index.value | 58 |
| abstract_inverted_index.0.03). | 186 |
| abstract_inverted_index.0–1. | 207 |
| abstract_inverted_index.NSCLC. | 272 |
| abstract_inverted_index.NSCLC; | 234 |
| abstract_inverted_index.before | 109 |
| abstract_inverted_index.better | 163 |
| abstract_inverted_index.cancer | 2, 26, 61 |
| abstract_inverted_index.factor | 13, 262 |
| abstract_inverted_index.growth | 12, 261 |
| abstract_inverted_index.hazard | 119 |
| abstract_inverted_index.kinase | 16, 265 |
| abstract_inverted_index.little | 34 |
| abstract_inverted_index.method | 115 |
| abstract_inverted_index.models | 120 |
| abstract_inverted_index.needed | 239 |
| abstract_inverted_index.points | 245 |
| abstract_inverted_index.values | 100, 143 |
| abstract_inverted_index.(0–1) | 160, 194, 210 |
| abstract_inverted_index.(NSCLC) | 27 |
| abstract_inverted_index.(hazard | 165 |
| abstract_inverted_index.Glasgow | 39, 251 |
| abstract_inverted_index.Methods | 77 |
| abstract_inverted_index.October | 94 |
| abstract_inverted_index.Results | 132 |
| abstract_inverted_index.albumin | 53, 106 |
| abstract_inverted_index.deaths. | 9 |
| abstract_inverted_index.further | 236 |
| abstract_inverted_index.leading | 5 |
| abstract_inverted_index.limited | 294 |
| abstract_inverted_index.overall | 129 |
| abstract_inverted_index.predict | 71 |
| abstract_inverted_index.protein | 50 |
| abstract_inverted_index.studies | 237 |
| abstract_inverted_index.various | 60 |
| abstract_inverted_index.whether | 68 |
| abstract_inverted_index.Although | 10 |
| abstract_inverted_index.December | 97 |
| abstract_inverted_index.advanced | 22 |
| abstract_inverted_index.analysis | 188 |
| abstract_inverted_index.efficacy | 155, 228, 258 |
| abstract_inverted_index.evaluate | 67, 124 |
| abstract_inverted_index.expected | 291 |
| abstract_inverted_index.findings | 247, 278 |
| abstract_inverted_index.however, | 235 |
| abstract_inverted_index.identify | 286 |
| abstract_inverted_index.interval | 171 |
| abstract_inverted_index.patients | 32, 83, 140, 202, 216, 287 |
| abstract_inverted_index.received | 90 |
| abstract_inverted_index.receptor | 14, 263 |
| abstract_inverted_index.response | 72, 297 |
| abstract_inverted_index.survival | 126, 130 |
| abstract_inverted_index.tyrosine | 15, 264 |
| abstract_inverted_index.validate | 241 |
| abstract_inverted_index.conferred | 161 |
| abstract_inverted_index.confirmed | 189 |
| abstract_inverted_index.effective | 20 |
| abstract_inverted_index.epidermal | 11, 260 |
| abstract_inverted_index.evaluated | 82 |
| abstract_inverted_index.findings. | 243 |
| abstract_inverted_index.harboring | 28, 86 |
| abstract_inverted_index.mutations | 88 |
| abstract_inverted_index.patients, | 135 |
| abstract_inverted_index.predicted | 153, 196, 212, 226, 256 |
| abstract_inverted_index.presented | 279 |
| abstract_inverted_index.receiving | 217 |
| abstract_inverted_index.response. | 37 |
| abstract_inverted_index.settings. | 62, 221 |
| abstract_inverted_index.treatment | 218, 268, 300 |
| abstract_inverted_index.Background | 0 |
| abstract_inverted_index.EGFR‐TKI | 91, 299 |
| abstract_inverted_index.confidence | 170 |
| abstract_inverted_index.determined | 102 |
| abstract_inverted_index.experience | 33, 293 |
| abstract_inverted_index.inhibitors | 17, 266 |
| abstract_inverted_index.initiation | 110 |
| abstract_inverted_index.mutations, | 30 |
| abstract_inverted_index.prognostic | 40, 57, 252 |
| abstract_inverted_index.‐mutated | 233, 271 |
| abstract_inverted_index.Conclusions | 222 |
| abstract_inverted_index.EGFR‐TKIs | 230 |
| abstract_inverted_index.Significant | 246 |
| abstract_inverted_index.monotherapy | 92 |
| abstract_inverted_index.multicenter | 80 |
| abstract_inverted_index.non‐small | 23 |
| abstract_inverted_index.0.33–0.96, | 183 |
| abstract_inverted_index.0.38–0.96, | 173 |
| abstract_inverted_index.C‐reactive | 49 |
| abstract_inverted_index.EGFR‐TKIs. | 76, 112 |
| abstract_inverted_index.EGFR‐TKIs; | 157 |
| abstract_inverted_index.Multivariate | 187 |
| abstract_inverted_index.first‐line | 220 |
| abstract_inverted_index.proportional | 118 |
| abstract_inverted_index.(EGFR‐TKIs) | 18, 267 |
| abstract_inverted_index.independently | 152, 195, 211, 225, 255 |
| abstract_inverted_index.respectively. | 149 |
| abstract_inverted_index.retrospective | 79 |
| abstract_inverted_index.significantly | 162 |
| abstract_inverted_index.Kaplan‐Meier | 114 |
| abstract_inverted_index.concentrations | 107 |
| abstract_inverted_index.concentrations, | 54 |
| abstract_inverted_index.cancer‐related | 8 |
| abstract_inverted_index.progression‐free | 125 |
| abstract_inverted_index.inflammation‐related | 45 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 89 |
| corresponding_author_ids | https://openalex.org/A5035023922, https://openalex.org/A5108560188, https://openalex.org/A5080241378, https://openalex.org/A5034689164, https://openalex.org/A5042736030, https://openalex.org/A5033780369, https://openalex.org/A5064369566, https://openalex.org/A5081624481, https://openalex.org/A5091454845, https://openalex.org/A5086397728 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 10 |
| corresponding_institution_ids | https://openalex.org/I165735259, https://openalex.org/I4210102403, https://openalex.org/I4210164148, https://openalex.org/I4210164827, https://openalex.org/I8588240 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8399999737739563 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.83302669 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |